Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glucuronic Acid SCHEMBL29065942 | 0.89 | GPR84 (0.46) | GPR84FFAR1MAPTLCKPPARD | |
| Glucuronic Acid SCHEMBL18320277 | 0.89 | DNM1 (0.42) | DNM1GPR84FFAR1EPHX2 | |
| Hexadecane SCHEMBL29065943 | 0.81 | PDE4A (0.58) | GPR84FFAR1MAPTLCKPPARD | |
| Glucuronic Acid SCHEMBL21295294 | 0.77 | PAOX (0.45) | ZDHHC20ZDHHC2 | |
| Glucuronic Acid SCHEMBL21295293 | 0.77 | PAOX (0.45) | ZDHHC20ZDHHC2 | |
| Glucuronic Acid SCHEMBL28731388 | 0.76 | PDE4A (0.39) | — | |
| Glucuronic Acid SCHEMBL29563844 | 0.76 | PDE4A (0.39) | — | |
| Lactic Acid SCHEMBL23174633 | 0.76 | DNM1 (0.60) | DNM1GPR84FFAR1MAPTLCK | |
| Lactic Acid SCHEMBL5934076 | 0.76 | DNM1 (0.60) | DNM1GPR84FFAR1MAPTLCK | |
| Lactic Acid SCHEMBL29600390 | 0.76 | DNM1 (0.60) | DNM1GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367705-A1 | NANOPARTICLES COMPRISED OF SHELLS ASSOCIATED WITH CHARGED ENTITIES AND FORMED FROM MONOMERS AND METHODS OF MAKING AND USING NANOPARTICLES | NEW YORK UNIVERSITY (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367705-A1 | NANOPARTICLES COMPRISED OF SHELLS ASSOCIATED WITH CHARGED ENTITIES AND FORMED FROM MONOMERS AND METHODS OF MAKING AND USING NANOPARTICLES | CHMP4B, RCC1, CD14 | DNM1 1422/4885GPR84 4430/4885FFAR1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.